Skip to main contentSkip to navigationSkip to search
Curasight

Press releases

2021

Positive data of uTREAT® in glioblastoma provides “green light” to proceed with next steps

June 24, 2021
 | Regulatory
The biodistribution results from Curasight A/S’ (“Curasight”) testing of uTREAT® for the treatment of glioblastoma are now available. The results are positive and provide “green light” to proceed to the next step.

SEB initiates commissioned research on Curasight A/S

June 18, 2021
 | Regulatory
Copenhagen, Denmark, 18 June 2021 – Curasight A/S (“Curasight” or the “Company”) has entered into an agreement with Skandinaviska Enskilda Banken AB (publ) (“SEB”) on commissioned research coverage.

Minutes from the Extraordinary General Meeting in Curasight A/S

June 1, 2021
 | Regulatory
Curasight A/S, CVR no. 35 24 93 89 (“Curasight” or the “Company”) held an extraordinary general meeting on 1 June 2021 at 11:00 (CET). Due to the COVID-19 situation, the extraordinary general meeting will be held as a completely electronic meeting without physical attendance.

Curasight presents at Bio Stock Life Science Spring Summit

May 26, 2021
 | Regulatory
Curasight A/S CEO Ulrich Krasilnikoff will present the company and its future plans at Bio Stock Life Science Spring Summit Thursday 27 May 2021. 

The presentation will be webcasted live 11:20 (CET), Thursday 27 May 2021.

Curasight presents at Erik Penser Bank – Temadag Medicinsk Bildteknik & Diagnostik

May 21, 2021
 | Regulatory
Curasight A/S CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company and its future plans at Erik Penser Bank – Temadag Medicinsk Bildteknik & Diagnostik.

The presentation will be webcasted live 10:55 (CET), Tuesday 25 May 2021.

Interim report January – March 2021 – Correction

May 20, 2021
 | Regulatory
Correction – Auditor’s review of the interim report on page 8.

Curasight A/S (“Curasight” or “the Company”) hereby publishes the interim report for the period January 1 – March 31, 2021. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Interim report January – March 2021

May 20, 2021
 | Regulatory
Curasight A/S (“Curasight” or “the Company”) hereby publishes the interim report for the period January 1 – March 31, 2021. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Notice of Extraordinary General Meeting

May 18, 2021
 | Regulatory
Copenhagen, Denmark, 18 May 2021 – Notice is hereby given of an extraordinary general meeting of Curasight A/S to be held on:

Tuesday, 1 June 2021 at 11:00 am CET

Curasight is awarded two prizes in Best IPO 2020 by the independent IPO Guide

May 17, 2021
 | Regulatory
Copenhagen, Denmark, 17 May 2021 – Affärsvärlden’s IPO Guide announced that Curasight A/S (“Curasight”) is awarded two prizes. The first for an excellent stock price development since the IPO and the second in the quality category. Affärsvärlden's IPO Guide examines all Swedish stock exchange listings. In 2020, 47 companies were listed on the stock exchange. Among the 7 small-cap companies Curasight’s stock price development stands out as excellent with an increase 110% above that of the OMXS30 index. In the quality category the jury awarded Curasight a honorable quality award as the company only received one flag by the IPO guide's reviewers compared to an average of 2.3 flags.

Curasight announces appointment of Dr. Kirsten Drejer as new board member

May 4, 2021
 | Regulatory
Curasight A/S (“Curasight”) is pleased to add a prominent and experienced biotech profile to its Board of Directors.
Load more